-- Frost & Sullivan to present global views on next-generation sequencing at Bio-IT World Conference & Expo '14
MOUNTAIN VIEW, Calif., April 15, 2014 /PRNewswire/ --
WHEN: | 11:00 a.m. EDT on Wednesday, April 30, 2014 |
LOCATION: | Bio-IT World Conference & Expo '14, Seaport World Trade Center, Boston, MA |
PRESENTER: | Frost & Sullivan Senior Vice President of Healthcare and Life Sciences Greg Caressi |
Companies along the spectrum of life science tools, informatics, genomics services, and clinical diagnostics industries continue flocking to the next-generation sequencing (NGS) market to take advantage of double-digit growth and an industry potentially worth billions in the coming years. Yet can this booming industry really support the more than 100 competitors and counting that serve the NGS informatics, data analysis, biological interpretation and clinical reporting portion of the market? It is imperative to evaluate the changing competitive landscape and uncover the real market information behind the hype to assess future market development.
Discussion Points
Supporting Quote
"Many large clinical organizations have ambitious plans for clinical sequencing, for example, sequencing every patient who walks in the door; however, payors must be on board for the market to truly take off," says Frost & Sullivan Senior Vice President of Healthcare and Life Sciences Greg Caressi. "Substantial evidence demonstrating sequencing's value and cost-savings advantages is necessary before it becomes routine in practices globally. Additionally, many chief information officers will take at least five years to realize the need for investing in clinical informatics with links to electronic health records. Because hospital administrators tend to think in terms of long-term investment cycles, this mentality will not take hold for many years."
Registration
Supporting Resources
For more information about Frost & Sullivan's global Healthcare practice, please visit: http://www.healthcare.frost.com.